MS patients have increased risks of developing other autoimmune diseases, necessitating careful treatment planning to balance efficacy and risk. Dimethyl fumarate, anti-CD20 antibodies, and ozanimod ...
The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results